Toronto, ON. (January 4, 2026) — OTO Fertility, a digital health platform developed by OTO Coach, is setting a new standard for reproductive care by using patented biometric and AI technology to predict fertility treatment outcomes with unprecedented clarity. Designed to support both patients and fertility clinics, the platform delivers personalized, real-time insights that reduce uncertainty and improve decision-making across fertility care in North America.
OTO’s core technology draws on more than 40 years of bioscience and space medicine, originally developed by NASA for astronauts and later refined for elite athletes. Bringing this level of physiological precision to fertility represents a breakthrough in reproductive support and signals a new standard of care for fertility patients.
OTO’s Fertility system includes a clinical-grade wearable biosensor and a proprietary FDA-approved app to help patients better understand and actively support their fertility success. By monitoring more than fifty biometric markers non-invasively, such as heart rate variability, nervous system regulation, and stress response, OTO identifies when the body is in an optimal “fertility zone”. The OTO Fertility Index offers a more personalized and accurate indicator of pregnancy success than traditional measures such as ovulation timing, age, BMI, or AMH, while also helping users see how everyday choices, including nutrition, supplements, and stress management, influence their readiness to conceive.
In fertility care, time is the one resource that cannot be replaced. Eggs cannot be replenished. Cycles cannot be repeated. Missed opportunities often come at an emotional, physical, and financial cost that patients carry for several years. Yet until now, fertility treatment has largely proceeded without a clear, quantifiable understanding of when a woman’s body is truly ready to conceive. OTO Fertility is the first platform to measure and translate that readiness into actionable insight, helping patients and providers reduce avoidable loss, unnecessary cycles, and the burden of proceeding without critical physiological context. In a field where every decision matters, having this level of precision is no longer optional, it’s foundational.
“Until now, there’s been no accurate way to predict fertility care based on what’s actually happening in the body in real time,” said Caleb Evans, CEO and Founder of OTO. “Our technology gives patients a personalized understanding of their body’s signals, restoring clarity, agency, and peace of mind, while providing clinicians with a powerful new layer of insight to support better outcomes. OTO doesn’t replace existing fertility protocols; it enhances them. And for the millions who have done everything right and still struggle to get pregnant, it can help unlock a path forward.”
The company’s NASA-derived bioscience and AI set a new benchmark in precision reproductive care. Through predictive insights, users can now understand how their daily habits such as nutrition, supplements, or stress management directly influence fertility and conception outcomes. For the first time, individuals can quantify the real impact of interventions like vitamin supplements or acupuncture on their reproductive readiness. The platform also supports ongoing optimization, providing personalized, data-driven recommendations based on biometric feedback to help patients reach OTO’s optimal fertility zone. These include tailored guidance on movement, recovery, and lifestyle adjustments designed to maximize conception potential.
The OTO Biosensor and OTO Life app are now available across North America at www.otofertility.com, with ongoing clinical programs currently underway. For more information visit www.otofertility.com.
For media and press inquires please visit press.otofertility.com
###
Media Contact:
Erin McKay
Director of Communications
P: 416-455-9960
E: erin.mckay@oto.coach
About OTO Fertility
OTO Fertility is a division of OTO Coach, a biometric health intelligence company rooted in elite human performance science. Headquartered in Toronto with offices in Vancouver and Helsinki, OTO uses AI, clinical-grade biosensing, and decades of physiological research to deliver personalized insights across fertility, recovery, and human performance. This launch marks the first phase of OTO’s global expansion and the beginning of a new, insight-driven era in fertility care. Learn more at www.otofertility.com.